System raises $20M to build vertically integrated peptide platform
What's the deal? SystemDealroom has a profile for this one. Try Dealroom → has raised $20 million to expand its vertically integrated peptide platform, which connects patients with US-licensed clinicians and pharmacy-compounded treatments. The round drew backing from Patron Fund, VineDealroom has a profile for this one. Try Dealroom →, CourtsideDealroom has a profile for this one. Try Dealroom →, Daybreak, SV Angel, and Will VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? System wants to own more of the peptide supply chain rather than run another direct-to-consumer telehealth brand. It already has a compounding pharmacy in its network and plans to add raw-ingredient, or API, manufacturing.
How it works: US-licensed clinicians evaluate patient health histories and set personalised protocols. Certified US pharmacies then compound the prescribed treatments and ship them directly to patients across all 50 states, subject to state telehealth rules.
The platform currently offers treatments including Glutathione, GHK-CU, MIC+B12, NAD+, and Sermorelin.
Why now? System points to a shifting regulatory environment: the Food and Drug Administration recently voted to add six reviewed peptides to a list of substances that licensed compounding pharmacies can legally prepare.
The company cites estimates placing the global peptide therapeutics market at roughly $140 billion in 2025 and $163 billion in 2026, a category it says has moved beyond niche biohacking communities.
Quality controls: System says its products are independently lab tested, its clinicians are background-checked and reviewed through the National Practitioner Data Bank, and its treatments are sourced through FDA-registered US compounding pharmacies.
"My vision was never to be another DTC telehealth brand, but to own more of the stack and build the foundation this category needs as it moves into the mainstream," said founder and chief executive officer Adam Steinle.
The signal: System is betting that vertical integration and trust-building will define the peptide market's move into the mainstream. It is positioning itself between high-cost concierge clinics and less structured sources of access — a gap Steinle argues "no single platform currently owns."
Read more: pulse2.com
